» Articles » PMID: 27181204

The C/EBPδ Protein is Stabilized by Estrogen Receptor α Activity, Inhibits SNAI2 Expression and Associates with Good Prognosis in Breast Cancer

Overview
Journal Oncogene
Date 2016 May 17
PMID 27181204
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia and inflammatory cytokines like interleukin-6 (IL-6, IL6) are strongly linked to cancer progression, and signal in part through the transcription factor Ccaat/enhancer-binding protein δ (C/EBPδ, CEBPD), which has been shown to promote mesenchymal features and malignant progression of glioblastoma. Here we report a different role for C/EBPδ in breast cancer. We found that the C/EBPδ protein is expressed in normal breast epithelial cells and in low-grade cancers. C/EBPδ protein (but not mRNA) expression correlates with estrogen receptor (ER+) and progesterone receptor (PGR) expression and longer progression-free survival of breast cancer patients. Specifically in ER+ breast cancers, CEBPD-but not the related CEBPB-mRNA in combination with IL6 correlated with lower risk of progression. Functional studies in cell lines showed that ERα promotes C/EBPδ expression at the level of protein stability by inhibition of the FBXW7 pathway. Furthermore, we found that C/EBPδ attenuates cell growth, motility and invasiveness by inhibiting expression of the SNAI2 (Slug) transcriptional repressor, which leads to expression of the cyclin-dependent kinase inhibitor CDKN1A (p21). These findings identify a molecular mechanism by which ERα signaling reduces the aggressiveness of cancer cells, and demonstrate that C/EBPδ can have different functions in different types of cancer. Furthermore, our results support a potentially beneficial role for the IL-6 pathway specifically in ER+ breast cancer and call for further evaluation of the role of intra-tumoral IL-6 expression and of which cancers might benefit from current attempts to target the IL-6 pathway as a therapeutic strategy.

Citing Articles

Identification of C/EBPδ-Modifying Compounds as Potential Anticancer Agents Using a High-Throughput Drug Screen.

Hartl L, Duitman J, Aberson H, Medema J, Bijlsma M, Spek C J Cell Mol Med. 2025; 29(3):e70287.

PMID: 39887610 PMC: 11783153. DOI: 10.1111/jcmm.70287.


Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.

Panda V, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S Cancers (Basel). 2025; 17(2).

PMID: 39858015 PMC: 11763662. DOI: 10.3390/cancers17020234.


FBXW7 in breast cancer: mechanism of action and therapeutic potential.

Chen S, Leng P, Guo J, Zhou H J Exp Clin Cancer Res. 2023; 42(1):226.

PMID: 37658431 PMC: 10474666. DOI: 10.1186/s13046-023-02767-1.


Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.

Balamurugan K, Poria D, Sehareen S, Krishnamurthy S, Tang W, McKennett L JCI Insight. 2023; 8(6).

PMID: 36757813 PMC: 10070121. DOI: 10.1172/jci.insight.156057.


C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC.

Hartl L, Roelofs J, Dijk F, Bijlsma M, Duitman J, Spek C Int J Mol Sci. 2023; 24(2).

PMID: 36675048 PMC: 9867044. DOI: 10.3390/ijms24021537.


References
1.
Zahnow C . CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med. 2009; 11:e12. PMC: 3095491. DOI: 10.1017/S1462399409001033. View

2.
Carroll J, Meyer C, Song J, Li W, Geistlinger T, Eeckhoute J . Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006; 38(11):1289-97. DOI: 10.1038/ng1901. View

3.
Bermejo-Rodriguez C, Perez-Caro M, Perez-Mancera P, Sanchez-Beato M, Piris M, Sanchez-Garcia I . Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. Genomics. 2005; 87(1):113-8. DOI: 10.1016/j.ygeno.2005.09.014. View

4.
Knupfer H, Preiss R . Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat. 2006; 102(2):129-35. DOI: 10.1007/s10549-006-9328-3. View

5.
Cardona-Gomez P, Perez M, Avila J, Garcia-Segura L, Wandosell F . Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol Cell Neurosci. 2004; 25(3):363-73. DOI: 10.1016/j.mcn.2003.10.008. View